News

A new health economic analysis from the landmark FIRE AND ICE Trial, sponsored by Medtronic plc, was published in the Journal of the American Heart Association. The data show that treating paroxysmal atrial fibrillation (AF) with cryoballoon...

CardioFocus, Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved the HeartLight Endoscopic Ablation System for the treatment of paroxysmal atrial fibrillation (AF) in Japan.  The HeartLight System is a...

AliveCor, the leader in FDA-cleared personal electrocardiogram (ECG) technology, announced a collaboration with Mayo Clinic to develop tools for medical and non-medical personnel to easily screen for long QT syndrome (LQTS) early by combining...

BIOTRONIK announced FDA approval and availability of the Intica DX and Intica cardiac resynchronization therapy (CRT)-DX implantable cardioverter defibrillator (ICD) systems. The launch of Intica CRT-DX extends the proven benefits of...

Technology for identifying at-risk atrial fibrillation (AF) patients was chosen as the winner of the inaugural Alexandria LaunchLabs Scholarship Award, which recognizes excellence in health care technology, entrepreneurship and business...

Cardiac Science, a leading global manufacturer of potentially life-saving automated external defibrillators (AEDs), announced that it has been granted approval by the Canadian regulatory agency, Health Canada, to begin marketing its fully...

BIOTRONIK has announced the launch of its Evity cardiac resynchronization therapy pacemaker (CRT-P) in the Japanese market. It is the company’s highest performing CRT-P with a battery life of almost 10 years. Quadripolar technology allows for...

Medical device company CathVision has signed a multi-million venture investment from Scandinavian-based investors VF Venture and Borean Innovation. The investment is directed at developing and market the company's superior electrophysiology...

Cardiologs Technologies SAS announced that it has received FDA clearance of its Cardiologs ECG Analysis Platform, a cloud-based cardiac monitoring-analysis web service powered by artificial intelligence (AI). Cardiologs aids physicians in...

Janssen Research & Development, LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for XARELTO® (rivaroxaban) to include a 10 mg once-daily dose for reducing...